YOLFTbeta
Moleculin Biotech Inc

Moleculin Biotech Inc

MBRX · NASDAQ · Healthcare / Biotechnology

7.87USD-0.19 (-2.36%)

Price History

Full chart

Market Stats

Previous Close8.06
Open8.00
Day Range7.71 – 8.10
52-Week Range0.161 – 15.75
Volume9.90K
Market Cap12.26M
P/E (TTM)0.04
Forward P/E0.00
EPS14.59
Dividend Yield0.00%
Beta1.92
50-Day Avg0.9037
200-Day Avg2.52

About

Moleculin Biotech, Inc., a late-stage pharmaceutical development company, engages in the development of therapeutic candidates for the treatment of tumors and viruses. Its lead drug candidate is Annamycin, an anthracycline, which is in clinical stage for the treatment of relapsed or refractory acute myeloid leukemia and soft tissue sarcoma lung metastases. The company is also developing WP1066 portfolio, including WP1066, WP1193, and WP1220, which are immune/transcription modulators designed to inhibit phosphorylated signal transducer and activator of transcription for brain tumors and pancreatic and other cancers. In addition, it is developing WP1122 portfolio, such as WP1122, WP1096, and WP1097 designed to exploit the uses of inhibitors of glycolysis comprising 2-deoxy-D-glucose that cut off the energy supply of tumors. The company was incorporated in 2015 and is headquartered in Houston, Texas.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOMr. Walter V. Klemp
  • Employees17
  • Headquarters5300 Memorial Drive, Houston, TX, United States, 77007, USA
  • Websitehttps://moleculin.com

Leadership

  • Mr. Walter V. KlempChairman, President & CEO · b. 1960
  • Mr. Jonathan P. Foster CPAExecutive VP & CFO · b. 1964
  • Dr. Donald H. Picker Ph.D.Chief Scientific Officer · b. 1946
  • Dr. Waldemar Priebe Ph.D.Co-Founder, Founding Scientist & Chairman of Scientific Advisory Board
  • Dr. John Paul Waymack M.D., Sc.D.Senior Chief Medical Officer · b. 1952

Financials

Income Statement

Currency: USD2015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue009.00K00000000
Growth (%)----100.00%-------
Cost of Revenue06.16K18.00K68.00K185.00K285.00K260.00K222.00K127.00K126.00K90.00K
Gross Profit0-6.16K-18.00K-68.00K-185.00K-285.00K-260.00K-222.00K-127.00K-126.00K-90.00K
Gross Margin---200.00%--------
Operating Expense738.23K3.88M8.63M14.96M17.34M19.46M22.71M30.42M29.50M26.52M25.01M
Operating Income-738.23K-3.88M-8.65M-15.03M-17.52M-19.74M-22.97M-30.64M-29.63M-26.64M-25.10M
Operating Margin---96144.44%--------
EBITDA-738.23K-3.88M-8.63M-14.96M-13.25M-19.54M-15.73M-28.89M-29.64M-21.64M-33.47M
EBITDA Margin---95944.44%--------
Net Income-748.36K-3.93M-9.80M-11.88M-13.21M-17.36M-15.89M-29.02M-29.77M-21.76M-33.56M
Net Income Margin---108944.44%--------
R&D260.42K1.50M4.54M9.73M11.01M12.76M14.42M18.97M19.49M17.73M15.89M
R&D as % of Total Revenue--50500.00%--------
Interest Expense043.21K008.15M13.00K7.07M1.61M---
Interest Expense % of Total Revenue--0.00%--------

Balance Sheet

Currency: USD2015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets28.09K16.39M19.48M19.59M25.23M29.16M84.09M57.42M38.22M16.93M22.13M
Total Liabilities772.79K1.43M2.37M5.31M9.66M11.27M5.10M5.23M12.14M10.95M7.12M
Total Equity-744.70K14.96M17.12M14.27M15.57M17.89M78.99M52.19M26.07M5.98M15.01M
Cash28.09K5.01M7.71M7.13M10.73M15.17M70.90M43.15M23.55M4.28M8.88M
Total Debt450.00K296.41K--379.00K277.00K159.00K451.00K574.00K478.00K359.00K
Net Debt421.91K-4.71M-7.71M-7.13M-10.36M-14.90M-70.74M-42.69M-22.98M-3.80M-8.52M

Cash Flow

Currency: USD2015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-423.51K-3.76M-7.32M-12.20M-17.20M-17.77M-18.95M-27.64M-24.10M-23.86M-22.73M
Investing Cash Flow232.30K-121.11K-28.00K-417.00K-51.00K-374.00K-19.00K-67.00K-124.00K-13.00K-
Financing Cash Flow451.60K8.87M10.06M12.04M20.85M22.55M74.72M-23.00K4.65M4.63M27.28M
Capital Expenditure21.00K21.47K28.00K417.00K52.00K376.00K19.00K67.00K124.00K13.00K0
Free Cash Flow-423.51K-3.79M-7.35M-12.62M-17.25M-18.15M-18.97M-27.71M-24.23M-23.88M-22.73M
Dividends Paid-00-------104.00K
FCF to OCF100.00%100.57%100.38%103.42%100.30%102.12%100.10%100.24%100.51%100.05%100.00%
Dividend Paid to FCF-0.00%0.00%--------0.46%

Earnings

Report DateAug 15, 2016Nov 21, 2016May 12, 2017Aug 14, 2017Nov 14, 2017Mar 28, 2018May 14, 2018Aug 10, 2018Nov 13, 2018Feb 21, 2019May 13, 2019Aug 16, 2019Nov 12, 2019Mar 19, 2020May 11, 2020Aug 12, 2020Nov 12, 2020Mar 24, 2021May 12, 2021Aug 11, 2021Nov 10, 2021Mar 24, 2022May 11, 2022Aug 12, 2022Nov 10, 2022Mar 22, 2023May 10, 2023Aug 10, 2023Nov 13, 2023Mar 22, 2024May 10, 2024Aug 13, 2024Nov 8, 2024Mar 20, 2025May 13, 2025Aug 12, 2025Nov 13, 2025Mar 19, 2026May 14, 2026Aug 13, 2026Nov 12, 2026
EPS Estimate--0.11-0.66---0.72-315.00-315.00-292.50-225.00-202.50-270.00-195.00-0.66-225.00-202.50-210.00-0.58-86.25-70.00-77.50-0.21-78.75-95.62-103.75-0.30-114.37-99.37-75.00-3.05-88.25-62.75-61.00-1.28-13.87-10.08-6.58-6.11-1.66-1.55-0.50
EPS Actual-0.08-0.12-0.72-0.19-0.14-0.96-254.25-450.00-180.00-225.00-315.00-192.60-211.05-0.48-227.70-189.63-224.66-0.26-75.00-71.40-79.50-0.09-90.00-96.82-112.50-0.23-103.76-75.94-71.25-5.02-50.50-42.50-71.25-0.56-17.25-12.25-0.684.83-3.54-1.40-
Surprise--9.09%-9.09%---33.33%19.29%-42.86%38.46%0.00%-55.56%28.67%-8.23%27.27%-1.20%6.36%-6.98%55.17%13.04%-2.00%-2.58%57.14%-14.29%-1.25%-8.43%23.33%9.28%23.58%5.00%-64.59%42.78%32.27%-16.80%56.60%-24.37%-21.53%89.67%178.99%-113.25%9.68%-
TimingAfter-hoursAfter-hoursAfter-hoursPre-marketPre-marketPre-marketAfter-hoursAfter-hoursPre-marketAfter-hoursAfter-hoursAfter-hoursPre-marketAfter-hoursAfter-hoursPre-marketAfter-hoursPre-marketPre-marketAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursPre-marketAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hours-After-hoursAfter-hours-

Key Statistics & Ratios

Market Cap12.26M
Enterprise Value3.73M
Trailing P/E0.04
Forward P/E0.00
PEG Ratio0.00
Price / Sales0.00
Price / Book0.92
EPS14.59
Book Value1.63
Revenue (TTM)0
Gross Profit (TTM)0
EBITDA-28.83M
Profit Margin0.00%
Operating Margin0.00%
Return on Equity-1371.64%
Return on Assets-84.57%
Shares Outstanding20.39M
Shares Float17.03M
Beta1.92
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Analyst Ratings

Buy
Based on 3 analystsTarget 12.00
  • Buy
    2
  • Hold
    1

Ownership Breakdown

Institutions
8.19%
Insiders
6.13%
Retail / Other
85.68%

Top Institutional Holders

  • Sabby Management LLC
    75.02K0.39%
  • Geode Capital Management, LLC
    32.33K0.17%
  • Vanguard Capital Management, LLC
    13.87K0.07%
  • HRT FINANCIAL LLC
    13.74K0.07%
  • Vanguard Fiduciary Trust Co
    6.07K0.03%
  • Rockefeller Capital Management L.P.
    4.42K0.02%
  • UBS Group AG
    3.41K0.02%
  • Tower Research Capital LLC
    1.83K0.01%
  • BlackRock Inc
    4910.00%
  • EFG International AG
    4340.00%
  • Newbridge Financial Services Group, Inc.
    1140.00%
  • SBI Securities Co Ltd
    430.00%
  • Morgan Stanley - Brokerage Accounts
    360.00%
  • Vanguard Global Advisers, LLC
    240.00%
  • FMR Inc
    30.00%
  • Caitong International Asset Management Co., Limited.
    20.00%

Top Fund Holders

  • Fidelity Extended Market Index
    27.44K0.86%
  • Fidelity Series Total Market Index
    7.99K0.25%
  • Fidelity Nasdaq Composite Index
    4.48K0.14%
  • Fidelity Total Market Index
    9150.03%

Stock Splits

  • Oct 20, 20261:20
  • Dec 1, 20251:25
  • Mar 22, 20241:15
  • Feb 1, 20211:6